A drug currently available in the clinic could be used to treat patients with an inherited form of cardiac arrhythmia, according to a study published in Nature Medicine.
CPVT -- a specific type of ventricular tachycardia -- is a potentially lethal form of arrhythmia. It is commonly linked to mutations in cardiac calcium channels known as ryanodine receptors. Pharmacological interventions against CPVT are often ineffective, but Björn Knollmann and his colleagues have now found that flecainide -- a drug already approved to treat other arrhythmias by acting on sodium channels -- prevents disease in a mouse model of CPVT by a new mechanism: the direct inhibition of calcium release mediated by cardiac ryanodine receptors.
Flecainide also prevented CPVT in two patients who had not responded to conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy against this condition.
Björn Knollmann (Vanderbilt University, Nashville, TN, USA)
Abstract available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking